New inhaled therapy aims to treat lung scarring with fewer side effects
NCT ID NCT06992661
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-stage trial is testing a single dose of an inhaled drug called RJ026 in 42 healthy volunteers and 42 people with interstitial lung disease (ILD). The goal is to see how the drug moves through the body and whether it is safe when delivered directly to the lungs via an inhaler, compared to taking it as a pill. The study will measure drug levels in blood and lung fluid over 24 hours and monitor for side effects over a week.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RJ026 inhaled powder
What this could lead to
If successful, this could lead to a safer, lung-targeted treatment for interstitial lung disease with fewer side effects than oral medication.
What could go wrong
This is a very early Phase 1 trial with only 84 participants. It primarily measures safety and drug levels, not whether the drug actually improves the disease. Many early-stage drugs fail to show benefit in later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.